What was Crescent Capital Bdc, Inc.’s price range in the past 12 months?
Crescent Capital Bdc, Inc. lowest stock price was $10.92 and its highest was $16.04 in the past 12 months.
What is Crescent Capital Bdc, Inc.’s market cap?
Crescent Capital Bdc, Inc.’s market cap is $418.94M.
When is Crescent Capital Bdc, Inc.’s upcoming earnings report date?
Crescent Capital Bdc, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 78 days.
How were Crescent Capital Bdc, Inc.’s earnings last quarter?
Crescent Capital Bdc, Inc. released its earnings results on May 13, 2026. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.419 by $0.001.
Crescent Capital Bdc, Inc. pays a Notavailable dividend of $0.42 which represents an annual dividend yield of 13.2%. See more information on Crescent Capital Bdc, Inc. dividends here
What is Crescent Capital Bdc, Inc.’s EPS estimate?
Crescent Capital Bdc, Inc.’s EPS estimate is 0.38.
How many shares outstanding does Crescent Capital Bdc, Inc. have?
Crescent Capital Bdc, Inc. has 36,845,950 shares outstanding.
What happened to Crescent Capital Bdc, Inc.’s price movement after its last earnings report?
Crescent Capital Bdc, Inc. reported an EPS of $0.42 in its last earnings report, beating expectations of $0.419. Following the earnings report the stock price went down -8.263%.
Which hedge fund is a major shareholder of Crescent Capital Bdc, Inc.?
Currently, no hedge funds are holding shares in CCAP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Crescent Capital BDC, Inc. is as a business development company private equity / buyouts and loan fund. It specializes in directly investing. It specializes in middle market. The fund seeks to invest in United States.
The call presented a balanced mix of proactive, constructive strategic actions and ongoing credit challenges. Positives included permanent fee reductions to improve long-term earnings resilience, a reset dividend framework with special dividends to address spillover, solid liquidity and a robust platform pipeline, and continued portfolio-level metrics that remained largely stable (86% rated 1 or 2; interest coverage 2.2x). Offsetting these were meaningful near-term headwinds: NAV declined ~4.35% QoQ, core NII declined ~15.6% from the prior quarter (to $0.38 before the waiver), nonaccruals increased (to 5.7% of cost and 3.6% of fair value) with concentration in select health care assets, and leverage sat marginally above target. Management emphasized conservative mark-to-market practices and active portfolio management. Overall, the positives (structural fee/dividend changes, liquidity, deployment opportunities and platform strength) are balanced by credit-related pressures and earnings softness, resulting in a neutral near-term outlook but with steps aimed at longer-term stabilization.View all CCAP earnings summaries